Immunosuppressive Drugs Market Exclusive Report on the Latest Trends and Opportunities in the Market By 2030
Immunosuppressive
Drugs Market Highlights
Immunosuppressive
drugs are antirejection medicines that obstruct or prevent activity of the
immune system. The growth of the global immunosuppressive drugs market is
driven by various factors such as the rising incidence rate of autoimmune
diseases and increasing cases of organ failures with the need for organ
transplantation. However, the high costs of transplantation procedures and the
side effects of the drugs are expected to curb the growth of the global immunosuppressive
drugs market.
According
to MRFR analysis, the global immunosuppressive drugs market is expected to reach USD 8658.21 million by 2030 at 7.34% CAGR during
the forecast period 2022-2030.
The
global immunosuppressive
drugs market is currently dominated by numerous
market players. The key players are involved in product launches and strategic
collaborations to strengthen their market positions. For instance, in May 2015,
Pfizer, Inc. was granted US Food and Drug Administration (FDA) approval for
Rapamune (Sirolimus) for the treatment of lymphangioleiomyomatosis (LAM).
Segmentation
The
global immunosuppressive drugs market report has been segmented based on drug type, route of
administration, application, and end user.
The
market, based on drug type, has been segmented into calcineurin inhibitors,
corticosteroids, antiproliferative agents, mTOR inhibitors, IMDH inhibitors,
and others. The calcineurin inhibitors segment is likely to hold the majority
share of the global immunosuppressive drugs market owing to the high efficacy
of these drugs. This drug class is the most preferred after organ
transplantation procedures. The corticosteroids segment is expected to be the
fastest-growing as medical professionals increasingly prefer these drugs.
The
market, by route of administration, has been bifurcated into intravenous, oral,
and others. The intravenous segment is expected to be the largest, while the
oral segment is projected to be the fastest growing. Key market players for increasingly
seeking approvals for their oral immunosuppressive drugs.
The
global immunosuppressive drug market has been segmented, based on application,
into autoimmune disease, organ transplant, and others. The autoimmune disease
segment is projected to be the largest due to the increasing occurrences and
growing incidence rates of autoimmune diseases such as rheumatoid arthritis,
multiple sclerosis, and systemic lupus erythematosus. The organ transplant
segment is expected to register the highest growth rate owing to the increased
number of transplant donors and the rising number of organ transplant
procedures. The organ transplant immunosuppressive drugs segment has been further divided into kidney
transplant, liver transplant, heart transplant, and others.
The
end user segments of the market are hospitals and clinics, organ transplant centres,
and others. The hospitals and clinics segment are expected to hold the largest
market share due to the rising number of patient admissions and the growing
number of hospitals in developing economies. The organ transplant canters
segment is expected to be the fastest growing; this growth can be attributed to
the increased use of immunosuppressants post-transplant procedures.
Immunosuppressive Drugs Market Players
Some of the key players in the global
immunosuppressive drugs market are Accord Healthcare (US), Astellas Pharma
(Japan), F. Hoffmann-La Roche AG (Switzerland), Genzyme Co. (US),
GlaxoSmithKline PLC (UK), Bristol-Myers Squibb Company (US), Glenmark
Pharmaceuticals, Inc (India), Mylan Laboratories Inc. (US), Novartis AG
(Switzerland), Pfizer Inc. (US), Actavis, Inc. (US), and Zydus Cadila (India).
Regional
Analysis
The
global immunosuppressive drugs market has been divided, by region, into the
Americas, Europe, Asia-Pacific, and the Middle East & Africa. The
immunosuppressive drugs market in the Americas has further been branched into
North America and Latin America, with the North American market divided into
the US and Canada. The immunosuppressive drugs market in the Americas is
projected to be the largest during the forecast period owing to the large
patient pool. The European immunosuppressive drugs market has been classified
as Western Europe and Eastern Europe. The Western European market has further
been categorized as Germany, France, the UK, Italy, Spain, and the rest of
Western Europe. The immunosuppressive drugs market in Asia-Pacific has been
segmented into Japan, China, India, South Korea, Australia, and the rest of
Asia-Pacific. The Asia-Pacific immunosuppressive is projected to be the
fastest-growing during the review period. The immunosuppressive drugs market in
the Middle East & Africa has been divided into the Middle East and Africa.
About Market
Research Future:
At Market Research
Future (MRFR), we enable our customers to unravel the complexity of various
industries through our Cooked Research Report (CRR), Half-Cooked Research
Reports (HCRR), & Consulting Services. MRFR team have supreme objective to
provide the optimum quality market research and intelligence services to our
clients.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,
5Th Floor,
New York, New York
10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment